Ipsen
Sign in to saveIpsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Key facts
- Company.name
- Ipsen
- Company.logo
- Logo_Ipsen.jpg
- Company.location
- Balard, Paris 15, France
- Company.industry
- Pharmaceutical
- Company.key_people
- Marc de Garidel (Non-executive Chairman) David Loew (Chief Executive Officer)
- Company.products
- List of medicines
- Company.revenue
- (2024)
- Company.operating_income
- (2024)
- Company.net_income
- (2024)
- Company.num_employees
- 5,300
- Company.homepage
- www.ipsen.com
- Company.foundation
- 1929
- Company.founder
- Henri Beaufour
- Company.type
- Public
- Company.traded_as
- CAC Mid 60 Component
via Wikipedia infobox
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1929
- Location
- Paris, France
- Status
- Active
GRID grid.476474.2 · ISNI 0000 0001 1957 4504
Wikidata facts
- Official name
- IPSEN
- Employees
- 5300
- Revenue
- 3400000000
- Official website
- www.ipsen.com
Show 4 more facts
- inception
- 1929-01-01
- social media followers
- 4864
- net profit
- 347000000
- number of viewers/listeners
- 667676
Sources (10)
via Wikidata · CC0
~15 min read
Article
11 sectionsContents
- History
- Controversies
- Financial Data
- Shareholding
- Medicines
- In Oncology
- In Rare Disease
- In Neuroscience
- Fondation Ipsen
- References
- External links
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.